Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Details of these study results…